|
VAQTA offers scheduling choices
VAQTA is indicated for active immunization against disease
caused by hepatitis A virus (HAV) in persons 12 months of
age and older. Primary immunization should be given at least
2 weeks prior to expected exposure
to HAV.
The dosing regimen for VAQTA 0.5 mL (~25U) consists of 2
doses, the first given at 12 months to 18 years of age, and
a booster dose given 6 to 18 months afterward.
Select safety information
VAQTA is contraindicated in individuals who are hypersensitive
to any component of the vaccine. Hepatitis A vaccine should
not be administered to persons with a history of a severe
reaction to a prior dose of hepatitis A vaccine or to a vaccine
component.
Individuals who develop symptoms suggestive of
hypersensitivity after an injection of hepatitis A vaccine
should not receive
further injections of the vaccine.
In combined clinical trials
involving healthy children 12 to 23 months of age and children
and adolescents 2 to 18
years of age, the most commonly reported complaints (>2%
of injections) in one or both of these groups were localized
injection-site reactions (pain/tenderness/soreness, warmth,
erythema, swelling), fever, diarrhea, vomiting, irritability,
upper respiratory infection, rhinorrhea, cough, rash, otitis
media, and headache.
An acute infection or febrile illness
may be reason for delaying use of VAQTA except when, in
the opinion of a physician,
withholding the vaccine entails a greater risk.
Safety and effectiveness in infants below 12 months of age
have not been established.
As with
any vaccine, vaccination with VAQTA may not result in a
protective response in all susceptible vaccinees. Before administering VAQTA, please read the Prescribing
Information.
|
